Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes.
Open Access
- 1 August 1996
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 98 (3) , 826-837
- https://doi.org/10.1172/jci118855
Abstract
The specificity of T cell help for B cell activation and differentiation is maintained by the brief expression on the T cell surface, following T cell receptor-mediated triggering, of CD40 ligand (CD40L). Interaction of T helper (Th) cell CD40L with B cell CD40 induces B cell activation, cell surface expression of activation antigens, proliferation, and initiation of immunoglobulin isotype switch. We predicted that in patients with systemic lupus erythematosus (SLE), in whom Th cell-dependent production of autoantibodies results in immune complex-mediated tissue damage, CD40L expression might be augmented, prolonged, or abnormally regulated. Baseline expression of CD40L was increased in some SLE patients studied, when compared with control subjects. While Th cells from normal subjects (n = 14) and rheumatic disease control patients (n = 9) showed maximal expression of CD40L, after in vitro activation with phorbol myristate acetate (PMA) and ionomycin, at 6 h of culture with diminished levels observed at 24 and 48 h, Th cells from SLE patients (n = 19) maintained high level cell surface expression of CD40L through 24 and 48 h of culture. The prolonged expression of CD40L was functionally significant, as 24 h-activated SLE T cells, when cocultured with target B cells, induced greater B cell surface CD80 (B7-1) expression than did 24 h-activated normal T cells. These results document impaired regulation of CD40L expression in SLE T cells and identify an important potential target for therapy in this systemic autoimmune disease.Keywords
This publication has 56 references indexed in Scilit:
- Studies on the interdependence of gp39 and B7 expression and function during antigen‐specific immune responsesEuropean Journal of Immunology, 1995
- Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease.Journal of Clinical Investigation, 1994
- Cyclosporin A inhibits CD40 ligand expression in T lymphocytes.Journal of Clinical Investigation, 1994
- The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndromeCell, 1993
- The two-signal model of lymphocyte activation twenty-one years laterImmunology Today, 1992
- Molecular analysis of the induction of immunoglobulin E synthesis in human B cells by interleukin 4 and engagement of CD40 antigen.The Journal of Experimental Medicine, 1992
- T-cell epitopes on the 70-kDa protein of the (U1)RNP complex in autoimmune rheumatologic disordersJournal of Autoimmunity, 1990
- T helper cell-induced CD23 (BLAST-2) expression: An activation marker for the high density fraction of human B cellsClinical Immunology and Immunopathology, 1989
- Human peripheral blood T helper cell-induced B cell activation results in B cell surface expression of the CD23 (BLAST-2) antigenCellular Immunology, 1989
- Immunopathologic Studies of Systemic Lupus Erythematosus. II. Antinuclear Reaction of γ-Globulin Eluted from Homogenates and Isolated Glomeruli of Kidneys from Patients with Lupus Nephritis *Journal of Clinical Investigation, 1967